{
Glaxosmithkline Export Ltd.

Companies

}
001122334455554433221100
001122334455554433221100

Pfizer's RSV vaccine sales decline but market share shows promising growth

Pfizer's RSV vaccine, Abrysvo, generated $356 million in sales in Q3, down from $375 million last year, but the company reported a growing market share, exceeding 50% of shipped volume. Despite challenges from CDC guidelines affecting older adult uptake, maternal vaccination is seeing increased momentum. Pfizer is also advancing next-generation pneumococcal vaccines amid competition from Merck and Vaxcyte.
BioPharma Dive
United States Dollar Vaxcyte, Inc. Glaxosmithkline Export Ltd. Pfizer Inc. Merck & Co., Inc. USA Albert Bourla Aamir Malik Mikael Dolsten Show more
Healthcare, Market Report
20:21 29.10.2024

GSK invests 300 million in bispecific antibody for potential lupus treatment

GSK is set to pay $300 million to license a bispecific antibody from Chimagen Biosciences, aimed at treating autoimmune diseases like lupus. Currently in Phase 1 testing for cancer, the drug targets B cells by engaging T cells, potentially offering a novel therapeutic option for B cell-driven conditions. GSK plans to initiate its own Phase 1 trial next year, pending regulatory approval.
BioPharma Dive
United States Dollar Glaxosmithkline Export Ltd. Chimagen Biosciences Merck & Co., Inc. CHN USA Joe Biden Tony Wood Show more
Healthcare, News Article
15:44 29.10.2024

gsk invests 800 million in us manufacturing amgen launches eylea biosimilar

GSK is investing $800 million to expand its manufacturing site in Marietta, Pennsylvania, focusing on sterile liquid vaccines and drug substances, with operations expected by 2027 and 2028. Amgen has set a list price of $1,665 for its Eylea biosimilar, Pavblu, launching without a legal settlement, which may lead to penalties if future rulings favor Regeneron. Meanwhile, Roche has partnered with Dyno Therapeutics for gene therapy advancements, and AbbVie is collaborating with Gideon Richter on neuropsychiatric treatments. Marinus Pharmaceuticals is laying off staff after its seizure drug ganaxolone failed to meet Phase 3 study goals.
BioPharma Dive
United States Dollar Hoffmann-La Roche AG AbbVie Inc. Amgen Inc. Glaxosmithkline Export Ltd. Marinus Pharmaceuticals, Inc. USA Ned Pagliarulo Brian Abrahams Jonathan Gardner Jacob Bell Show more
Healthcare, Market Report
16:35 25.10.2024

sanofi to sell controlling stake in consumer health business to cd&r

Sanofi is moving forward with a deal to sell a controlling 50% stake in its consumer health business, Opella, to Clayton Dubilier & Rice for approximately €16 billion ($17.3 billion). Bpifrance will hold a 2% minority stake, ensuring job security in France amid concerns over potential job losses. The transaction is expected to close by Q2 2025, allowing Sanofi to focus on its biopharmaceuticals.
BioPharma Dive
Euro Pfizer Inc. Clayton, Dubilier & Rice LLC Johnson & Johnson Sanofi Novartis AG Bpifrance Glaxosmithkline Export Ltd. FRA USA Antoine Armand Paul Hudson Show more
Finance & Economy, News Article
18:23 21.10.2024

gsk sues moderna for alleged infringement of mRNA vaccine patents

GSK is suing Moderna for allegedly infringing on seven patents related to mRNA vaccine technology, which were developed by a team led by Christian Mandl during his time at Novartis. GSK claims that Moderna's success in rapidly developing its COVID-19 vaccine relied on these patented methods. The lawsuit seeks unspecified damages and reimbursement for legal costs.
BioPharma Dive
United States Dollar Pfizer Inc. BioNTech SE Novartis AG Glaxosmithkline Export Ltd. Moderna, Inc. USA DEU Christian Mandl Andrew Geall Show more
Regulatory & Legal, News Article
12:59 16.10.2024

GSK reports positive Phase 3 results for chronic nasal condition drug

GSK announced positive results from two Phase 3 trials of its antibody drug depemokimab for chronic rhinosinusitis with nasal polyps (CRSwNP), showing significant suppression of nasal polyp growth and improved nasal obstruction compared to placebo. The drug, which targets IL-5, is also being studied for asthma and other inflammatory diseases, with potential peak annual sales exceeding £3 billion if approved. Detailed trial results will be presented at an upcoming scientific congress.
BioPharma Dive
British Pound Sterling Sanofi Regeneron Pharmaceuticals, Inc. Glaxosmithkline Export Ltd. GBR USA Kaivan Khavandi Show more
Healthcare, News Article
14:01 14.10.2024

sanofi in talks to sell consumer health business to private equity firm

Sanofi is in negotiations with private equity firm Clayton Dubilier & Rice to sell a 50% controlling stake in its consumer health business, Opella, potentially valued at around €15 billion ($16.4 billion). This sale would allow Sanofi to focus more on its biopharmaceutical operations, which generated over €18 billion in sales in the first half of the year. Opella, known for products like Allegra and Icy Hot, operates in 100 countries and employs over 11,000 people.
BioPharma Dive
Euro United States Dollar Clayton, Dubilier & Rice LLC McKesson Corporation Glaxosmithkline Export Ltd. Pfizer Inc. Merck & Co., Inc. Novartis AG Sanofi Johnson & Johnson FRA USA François Roger Merck & Co. Show more
Finance & Economy, News Article
13:47 11.10.2024
Trending
Subcategory
Startups & Entrepreneurship Industry Trends Corporate News Private Equity Deals Retail and Consumer Goods Supply Chain Management Global Trade Developments CEO Changes Government Economic Policies Corporate Social Responsibility Industry Mergers & Acquisitions Workplace Trends Energy Sector Developments Venture Capital Investments Fintech Startups Finance Mergers & Acquisitions AI Innovations Market Analysis and Predictions Intellectual Property Laws Central Bank Actions
Countries:
IND USA CHN SAU ARE SGP JPN QAT EGY MYS IDN GBR KOR BRA HKG VNM TWN DEU FRA IRL
Companies:
Apple Inc. NVIDIA Corporation Google Inc. Amazon.com, Inc. Tesla, Inc. Salesforce, Inc. Garuda Aerospace Ltd. Huawei Technologies CO. Ltd. Bharti Airtel Ltd. XPeng Inc. Microsoft Corporation Venturewave Capital NO.1 Ltd. Semler Scientific, Inc. TENCENT Wipro Ltd OpenAI ERC USD Orange S.A. IDBI Bank Limited Standard Chartered Bank LENOVO GROUP
Currencies:
United States Dollar Indian Rupee Chinese Yuan Euro Saudi Riyal Japanese Yen Malaysian Ringgit British Pound Sterling Mexican Peso Brazilian Real New Taiwan Dollar Bahraini Dinar Qatari Riyal Pakistani Rupee Kuwaiti Dinar Vietnamese Đồng South Korean Won Algerian Dinar
People:
Donald Trump Mark Zuckerberg Bisrat Degefa He Xiaopeng Abdel Fattah El-Sisi Anmol Singh Jaggi Puneet Singh Jaggi Sari Sabban David Watkins Simon Moon Anas Algahtani Matt Jones Ayman Hamdan Elon Musk Allen Law Xi Jinping Anwar Hussain Sultan Ibrahim ibni Sultan Iskandar Prashant Joshi Albinder Dhindsa

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.